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Abstract
Background: Increased plasma levels of cellular adhesion molecules (CAMs) have been shown to be predictors of
all cause mortality in individuals with chronic renal failure [1,2] and patients with end-stage renal disease receiving
haemodialysis [3]. In renal transplant recipients the predictive value of CAMs has not been well characterised. The
aim of this study was to assess the relationship between CAMs and all-cause mortality during prospective follow-
up of a renal transplant cohort.
Methods: A total of 378 renal transplant recipients were recruited between June 2000 and December 2002.
Soluble vascular CAM-1 (VCAM) and soluble intercellular CAM-1 (ICAM) were measured at baseline and prospective
follow-up data was collected at a median of 2441 days after enrolment.
Results: In univariate survival analysis the renal transplant recipients with a VCAM or ICAM concentration in the
lowest third were significantly more likely to have survived at follow-up (p < 0.001 and p = 0.009 respectively). In
multivariate survival analysis VCAM and ICAM remained significant independent predictors of mortality following
adjustment for traditional cardiovascular risk factors, hsCRP and estimated GFR (p = 0.030 and p = 0.037
respectively).
Conclusions: The results of this prospective study are the first to show that the CAMs, ICAM and particularly
VCAM, are significant independent predictors of mortality in patients with a renal transplant.
Background
Patients with chronic kidney disease (CKD) have an
increased prevalence of atherosclerosis as compared to
the general population. However traditional cardiovascu-
lar risk factors do not adequately account for the
increased burden of vascular disease in persons with
CKD [4]. Since inflammation has been implicated in all
stages of the development of atherosclerosis [5], atten-
tion has been focused on molecules involved in inflam-
matory pathways and the utility of such biomarkers to
identify individuals at increased risk of cardiovascular
events.
Cell-to-cell interactions are critical at every phase in
the development of the atherosclerotic plaque and cellu-
lar adhesion molecules are essential mediators in this
process, playing a central role in the recruitment of
inflammatory cells to the site of atheroma development
[6].
Following activation, cellular adhesion molecules are
shed from the surface of endothelial cells [7] and can be
measured in plasma [8]. Soluble cellular adhesion mole-
cules (CAMs) therefore represent promising biomarkers
that may reflect underlying endothelial activation and
vascular inflammation [9].
Many factors have been shown to alter expression of
cellular adhesion molecules. These include hypertension
[10] immunosuppressive therapy [11], autoimmune dis-
ease [11-13] and cell mediated allograft rejection [14,15].
However increased plasma levels of CAMs have been
identified in persons with atherosclerotic disease [6] and
elevated concentrations of CAMs are significant predic-
tors of future death from cardiovascular causes among
patients with documented coronary artery disease [16].
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with chronic kidney disease and reduced glomerular fil-
tration rates [17,18]. In pre-dialysis patients, soluble
intercellular CAM-1 (ICAM) [1,2] and soluble vascular
CAM-1 (VCAM) [2] have been shown to be indepen-
dent predictors of mortality. Similarly, CAMs have been
reported to be predictors of all cause mortality in
patients with end-stage renal disease receiving haemo-
dialysis [3].
However, the predictive value of CAMs has not been
well defined in renal transplant recipients. We hypothe-
sised that CAMs would predict risk of death in patients
with a renal transplant. The aim of this study therefore
was to assess the relationship between the CAMs,
ICAM and VCAM, and all-cause mortality during the
prospective follow-up of a renal transplant cohort.
Methods
Between June 2000 and December 2002, 378 renal
transplant recipients were enrolled into this observa-
tional prospective study. Participants were recruited
from the renal transplant clinics at Belfast City Hospital
and Antrim Area Hospital in Northern Ireland, United
Kingdom.
The study was approved by the Research Ethics Com-
mittee Queen’s University Belfast and fully informed
written consent was obtained from each participant
p r i o rt oe n r o l m e n t .P a t i e n t sw e r ee l i g i b l ef o re n t r yi f
they had a functioning renal transplant present. No for-
mal exclusion criteria were imposed. However, patients
who were clinically unwell or had signs of sepsis at
initial assessment were deferred until a subsequent clinic
re-assessment.
All the renal transplant patients recruited to this study
were greater than 2 months post-renal transplant and
94% were recruited more than 12 months after trans-
plant surgery. All participants had stable graft function
and were on standard immunosuppression regimens.
The 378 renal transplant recipients enrolled in this
study represented 71.7% of all patients with a function-
ing renal transplant in Northern Ireland at the end of
2002 and 98% of all renal transplant recipients attending
the transplant clinics at Belfast City Hospital and
Antrim Area Hospital. The patients not enrolled either
did not consent to participate in the study or, more
commonly, were attending renal transplant clinics at
other geographically distant hospitals in the Northern
Ireland region.
At enrolment, with the assistance of a research nurse,
each participant completed a cardiovascular risk assess-
ment questionnaire. This recorded drug history, the pre-
sence of traditional cardiovascular risk factors (age,
gender, diabetes and smoking history) and history of
vascular disease. Prior vascular disease was defined as
history of stroke, myocardial infarction, coronary artery
bypass grafting, angioplasty, amputation for peripheral
vascular disease or angiographic evidence of athero-
sclerotic vascular disease.
Each participant also had a measurement of blood
pressure. This was recorded as the average of the last
three blood pressure measurements (measured using
Disytest sphygmomanometer Welch-Allyn, Buckingham-
shire, UK) assessed at the renal transplant clinic.
A fasting blood sample was obtained from each parti-
cipant and stored at -70°C until biochemical analysis.
Biochemical Analyses
VCAM and ICAM were measured in plasma samples
using a commercially available solid phase sandwich
ELISA technique (Diaclone; available from IDS, Tyne
and Wear, UK). The within run coefficient of variation
for VCAM was 3% and the between run coefficient of
variation was 10%. The within run coefficient of varia-
tion for ICAM was 1.2% and the between run coefficient
of variation was 7.1%.
Serum total cholesterol and high density lipoprotein
(HDL) cholesterol were measured using VITROS slides
and analysed using a VITROS 700 System (Ortho Clini-
cal Diagnostics, Rochester, NY, USA).
Serum creatinine was measured using the VITROS
Slide System and the VITROS 950 analyser system
(Ortho Clinical Diagnostics, Rochester, NY, USA).
Detection range for creatinine was 4 - 1238 μmol/l and
within lab coefficient of variation was 1.1%. Estimated
glomerular filtration rate (eGFR) was calculated for all
patients using the 4-variable MDRD equation [19]:
eGFR (ml/min/1.73 m2) = 186 × (serum creatinine[umol/l/89]) -1 . 1 5 4
× Age−0.203 × (0.742 if female) × (1.21 if African American).
High sensitivity C reactive protein (hsCRP) was mea-
sured using a high sensitivity immunoturbidimetric
assay (Randox, Crumlin, UK). Samples were analysed
using a Roche Cobas Fara (Roche, Basel, Switzerland).
All 378 participants had measurements for VCAM,
ICAM, total cholesterol, HDL cholesterol and creatinine.
375 participants had a measurement for hsCRP.
Prospective Data Collection
The collection of prospective follow-up data was com-
pleted in April 2008 at a mean of 2243 days and a med-
ian of 2441 days after enrolment. The longest period of
follow-up after recruitment to the study was 2844 days.
Mortality data, including date of death, where applic-
able, was available for all participants. This information
was obtained from the mortality data recorded on the
Regional Nephrology Database at Belfast City Hospital
and via letter and direct telephone contacts with the
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ents enrolled in this study. No patients were lost to fol-
low up.
Statistical Analyses
Data analysis was performed using SPSS (version 11.0
Chicago, Illinois, USA). Kolmogorov-Smirnoff analysis
was used to test if variables were normally distributed.
Logarithmic transformation was performed for variables
that did not conform to a normal distribution. For nor-
mally distributed variables data is expressed as arith-
metic mean +/- standard deviation (SD). For those
variables that were not normally distributed data is
expressed as median with the interquartile range in
brackets. The significance of differences between two
groups was assessed using independent samples t-test
for normally distributed variables. A two-tailed p value
<0.05 was considered to be statistically significant.
Kaplan-Meier analysis with log rank test was used for
univariate survival analysis. As there are no established
reference values for either VCAM or ICAM, these vari-
ables were banded into thirds prior to inclusion in survi-
val analysis.
A Cox Regression model was used for multivariate
survival analysis. As cardiovascular disease is the leading
cause of death in patients with a renal transplant [20],
multivariate survival analysis was performed including
traditional cardiovascular risk factors as co-variates.
Given the size of the study population, traditional cardi-
ovascular risk factors were banded into thirds prior to
inclusion in the Cox Regression model. Since the risk of
cardiovascular disease is also associated with hsCRP and
eGFR, these variables were also included as co-variates,
banded into thirds, in the Cox Regression analysis.
Results
Characteristics of the participants at enrolment to this
study are shown in Table 1.
All participants were white, 243 (64%) were male, 72
(19%) were smokers and 54 (14%) had diabetes. 12 (3%)
participants had received a pre-emptive renal transplant
and 366 (97%) participants had been on dialysis prior to
renal transplantation.
A minority, 84 (22%), of participants had a known his-
tory of cardiovascular disease at enrolment. Of those
with a history of cardiovascular disease at enrolment,
VCAM but not ICAM, was significantly higher as com-
pared to those who had no known history of cardiovas-
cular disease at enrolment (VCAM: 1731, (1290, 2666)
ng/ml vs. 1443 (1127, 2097) ng/ml p = 0.011 and
ICAM: 993 (740, 1366) ng/ml vs. 917 (635, 1256) ng/ml
p = 0.151).
As participants were transplanted between 1968 and
2001, their immunosuppression mainly reflected the
drug therapy available at the time of transplantation.
Consequently wide combinations of immunosuppression
regimens were in use in this study population. However,
258 renal transplant recipients were prescribed a calci-
neurin inhibitor. There was no significant difference in
VCAM or ICAM concentration in those transplant reci-
pients prescribed a calcineurin inhibitor as compared to
those not prescribed a calcineruin inhibitor (VCAM:
1505 (1167, 2182) ng/ml vs. 1564 (1062, 2108) ng/ml p
= 0.334 and ICAM: 909 (628, 1229) ng/ml vs. 976 (682,
1445) ng/ml p = 0.102).
At follow-up 305 participants were alive and 73 parti-
cipants had died. Based on survival at follow-up patients
were divided into two groups; group 1, deceased (n =
73) and group 2, survivors (n = 305). As shown in
Table 2, significant differences included that those who
had died during follow-up were older, more likely to be
diabetic, have had a history of cardiovascular disease at
enrolment, had lower eGFR, higher systolic blood pres-
sure, and higher hsCRP levels as compared to those
who were still alive at follow-up. Similarly, VCAM and
ICAM concentration at enrolment were significantly
higher in those renal transplant recipients who had died
at follow-up. There was no significant difference in time
from renal transplant in those participants who had died
at follow-up as compared to those who were still alive at
follow-up: 9 (4-14) years vs. 7 (3-12.5) respectively, p =
0.056,
Of the 73 renal transplant recipients who had died, 27
had died of a cardiovascular cause, 36 from a non-cardi-
ovascular cause and for 10 participants cause of death
could not be accurately established. There was no signif-
icant difference in VCAM or ICAM concentration in
those renal transplant recipients who had died of a car-
diovascular cause as compared to those who had died of
a non-cardiovascular cause (VCAM 2055 (1422, 2759)
ng/ml vs. 2478 (1340, 3329) ng/ml p = 0.54 and ICAM
Table 1 Biological and biochemical characteristics of the
renal transplant recipients enrolled in this study
Characteristic Distribution
Age (yrs) 47.3 +/- 14.3
Systolic blood pressure (mmHg) 132 +/- 14
Diastolic blood pressure (mmHg) 80 +/- 8
Total cholesterol (mmol/l) 5.2 +/- 1.0
HDL cholesterol (mmol/l) 1.4 +/- 0.4
Creatinine (μmol/l) eGFR (ml/min/m
2) 130 (106-160) 52.5 +/- 20.2
hsCRP (mg/l) 1.9 (0.9, 4.6)
VCAM (ng/ml) 1510 (1151, 2156)
ICAM (ng/ml) 928 (664, 1263)
Time post transplant (years) 7 (3-13)
Time on dialysis pre-transplant (months) 13 (8-27)
Results expressed as arithmetic mean +/- standard deviation or median (inter-
quartile range).
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0.10).
A ss h o w ni nF i g u r e1a n dF i g u r e2 ,i nu n i v a r i a t es u r -
vival analysis those renal transplant recipients with a
VCAM or ICAM concentration in the lowest third were
significantly more likely to have survived at follow-up as
compared to those transplant recipients with a VCAM
or ICAM concentration in the middle or highest third.
In multivariate Cox Regression analyses, as shown in
Table 3 and Table 4, VCAM and ICAM remained
significant predictors of mortality following adjustment
for traditional cardiovascular risk factors, hsCRP and
eGFR.
As VCAM was significantly higher in those renal
transplant recipients who had a history of cardiovascular
disease at enrolment, history of vascular disease at
enrolment was also included as a co-variate in survival
analysis. VCAM and ICAM remained significant predic-
tors of outcome following adjustment for history of vas-
cular disease at enrolment (Table 3 and Table 4).
Table 2 Differences in the renal transplant recipients who had died compared to those alive at follow-up
Deceased
(n = 73)
Survivors
(n = 305)
Significance
Age (yrs) 57.4+/- 14.1 45.5 +/- 13.5 <0.001**
Male gender
Cardiovascular disease at enrolment
45
33
198
51
0.773
<0.001**
Systolic blood pressure (mmHg) 135 +/- 14 131 +/- 14 0.031*
Diastolic blood pressure (mmHg) 78 +/- 6 79 +/- 7 0.067
Total cholesterol (mmol/l) 5.2 +/- 1.1 5.3 +/- 1.0 0.478
HDL cholesterol (mmol/l) 1.4 +/- 0.5 1.4 +/- 0.4 0.717
Diabetic 17 37 0.014*
Smokers 13 59 0.764
Creatinine (μmol/l)
eGFR (ml/min/m
2)
144(110-212)
45.9+/- 24.2
129(106-154)
53.9 +/- 19.0
0.011*
0.009**
hsCRP (mg/l) 3.8 (1.9, 9.9) 1.7 (0.8, 3.9) <0.001**
VCAM (ng/ml) 2120(1476, 3136) 1428 (1109, 2025) <0.001**
ICAM (ng/ml) 1061 (816, 1415) 900 (610, 1248) 0.003**
Results expressed as arithmetic mean +/- standard deviation or median (inter-quartile range). Levels of significance (* p < 0.05, ** p < 0.01).
Figure 1 Kaplan-Meier survival curve for renal transplant recipients stratified by VCAM concentration banded into thirds (p < 0.001).
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Although cardiovascular disease remains the leading
cause of death in patients with a renal transplant, tradi-
tional cardiovascular risk factors do not adequately
account for the increased prevalence of vascular disease
in this population [4]. An improved understanding of
the pathophysiology of cardiovascular disease in this
population is therefore critical to help identify mechan-
isms by which the burden of vascular disease could be
reduced.
Although there have been prior publications reporting
associations between CAMs and mortality in chronic
renal failure and dialysis patients [1-3], the predictive
value of CAMs has not been well defined in renal trans-
plant recipients. We hypothesised that CAMs would
predict risk of death in patients with a renal transplant
and the aim of this study was therefore to assess the
relationship between the CAMs, ICAM and VCAM, and
all-cause mortality during the prospective follow-up of a
renal transplant cohort.
CAMs are essential mediators in the process of ather-
osclerosis [6]. However, although elevated concentra-
t i o n so fC A M sa r ef o u n di np a t i e n t sw i t h
atherosclerosis [21], in our study we found that VCAM,
but not ICAM, was significantly higher in those renal
transplant recipients with a history of cardiovascular dis-
ease at enrolment.
Nevertheless, in patients with chronic kidney disease,
VCAM and ICAM have been shown to be independent
predictors of mortality [2] and in the renal transplant
recipients enrolled in our study VCAM and ICAM were
indeed significant predictors of all-cause mortality.
Although it has been reported that the predictive
power of CAMs for coronary artery disease is markedly
Figure 2 Kaplan-Meier survival curve for renal transplant recipients stratified by ICAM concentration banded into thirds (p = 0.009).
Table 3 Renal transplant recipient survival analyses
stratified by VCAM (abbreviation: CI, confidence interval)
Kaplan-Meier Cox Regression Analysis
Significance Significance Exp(B) CI
VCAM
a
<1272 ng/ml <0.001** 0.001** 1
1272-1972 ng/ml 1.7 0.83, 3.51
>1972 ng/ml 3.3 1.7, 6.4
VCAM
b
<1272 ng/ml <0.001** 0.030* 1
1272-1972 ng/ml 1.5 0.73, 3.16
>1972 ng/ml 2.4 1.21, 4.81
VCAM
c
<1272 ng/ml <0.001** 0.049* 1
1272-1972 ng/ml 1.4 0.6, 2.9
>1972 ng/ml 2.2 1.1, 4.5
Levels of significance (* p < 0.05, ** p < 0.01).
aCox Regression analysis adjusted for age, gender, smoking, diabetes, systolic
blood pressure, total cholesterol and HDL cholesterol.
bCox Regression analysis adjusted for age, gender, smoking, diabetes, systolic
blood pressure, total cholesterol, HDL cholesterol, eGFR and hsCRP.
cCox Regression analysis adjusted for age, gender, smoking, diabetes, systolic
blood pressure, total cholesterol, HDL cholesterol, eGFR, hsCRP and history of
vascular disease at enrolment
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vascular risk factors [22] VCAM and ICAM concentra-
tion remained significant predictors for mortality in the
renal transplant recipients enrolled in our study even
after adjustment for these risk factors.
Interestingly, although CAMs are associated with car-
diovascular disease, there was no significant difference
in VCAM or ICAM concentration in those renal trans-
plant recipients who had died of a cardiovascular cause
as compared to those who had died of a non-cardiovas-
cular. However, as there were relatively few deaths in
each of these 2 groups, we hypothesise that further fol-
low-up may yield more significant results.
Elevated concentrations of CAMs are found in
patients with chronic kidney disease [17,18,23]. How-
ever, in the renal transplant recipients enrolled in our
study, VCAM and ICAM remained significant predictors
of outcome following adjustment for renal function (glo-
merular filtration rate). Therefore, despite the associa-
tion reported between renal function and CAM
concentration, the data from our study demonstrate that
CAMs provide additional prognostic information inde-
pendent of renal function.
Elevated levels of ICAM and particularly VCAM have
been found to be significantly related to future death
from cardiovascular causes among patients with docu-
mented coronary artery disease [16]. In the renal trans-
plant recipients enrolled in this study, those with a
VCAM or ICAM concentrations in the lowest third had
the best survival. Of note, risk of mortality showed a
step-wise increase with increasing concentration of
VCAM. However, the risk of all-cause mortality in renal
transplant recipients with an ICAM concentration in the
middle third was similar to the risk for those with an
ICAM concentration in the highest third.
We believe that this two-centred prospective study,
representative of the renal transplant recipients in
Northern Ireland has yielded interesting results. Con-
founding factors were limited by recruiting patients with
stable graft function who were clinically well, more than
2 months post-transplant, on standard immunosuppres-
sion regimens. In addition, the significant biological and
biochemical differences between survivors and deceased
were included as co-variates in multivariate Cox Regres-
sion survival analysis. Selection bias was minimised by
lack of formal exclusion criteria.
We acknowledge that there are some limitations to our
study. This study was performed in a white renal trans-
plant population in one geographical region of the United
Kingdom. Therefore the applicability or generalisability
of the results of this study to other geographical regions
or ethnic groups is not established. Also, although data
on history of cardiovascular disease was recorded, infor-
mation on other co-morbidities which could impact on
mortality was not recorded at enrolment.
Nevertheless, this prospective cohort study of renal
transplant recipients has generated interesting and sig-
nificant results linking elevated concentrations of CAMs
with subsequent mortality.
Conclusion
CAMs are biochemical markers which reflect underlying
endothelial activation and vascular inflammation [9]. Our
study provides support for these as key mechanisms contri-
buting to injury and death in renal transplant recipients.
We believe we are the first group to show that the CAMs,
ICAM and in particular VCAM, are significant independent
predictors of all-cause mortality in patients with a renal
transplant. We believe that the results of this study are
worthy of further investigation in another population of
renal transplant recipients and identifying agents which tar-
get these processes may prove to be an important strategy
to improve the longevity of patients with a renal transplant.
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